DNAJC12

DNAJC12 is a cytoplasmic J-domain co-chaperone that maintains the stability and catalytic competence of the aromatic amino acid hydroxylase family, coupling client recognition to Hsp70-cycle activation (PMID:28132689, PMID:40113792). It directly binds phenylalanine hydroxylase (PAH), tyrosine hydroxylase (TH), and tryptophan hydroxylases (TPH1, TPH2), and its loss reduces hydroxylase protein levels and enzyme activity post-transcriptionally, since hydroxylase mRNA is unchanged in knockout animals (PMID:28132689, PMID:39695187, PMID:39923104). Structurally, the co-chaperone engages the regulatory regions of these enzymes without occluding their active sites: two DNAJC12 monomers embrace the regulatory-domain dimers of the TH tetramer, while four monomers bind the L-Phe-activated PAH tetramer, protecting both from aggregation and preserving activity and feedback regulation, with the C-terminal region required for client binding (PMID:40113792). DNAJC12 partners with the cytosolic Hsc70 (HSPA8) chaperone and stimulates its ATPase activity only when complexed with its client substrate, thereby coupling client engagement to chaperone activation (PMID:24122553, PMID:40113792). Beyond client binding it also forms a complex with GCH1, the rate-limiting enzyme of BH4 cofactor synthesis, and its loss reduces GCH1 levels and dopaminergic and serotonergic neurotransmitter output (PMID:40447642). Loss-of-function mutations in DNAJC12 destabilize PAH and other hydroxylases, producing hyperphenylalaninemia with central and peripheral monoamine neurotransmitter deficiency (PMID:28132689, PMID:39695187). In cancer cells DNAJC12 has been linked to HSP70-dependent AKT activation and to glycolytic and β-catenin signaling (PMID:38306757, PMID:33907820).

1. 2014 Medium

   Before its client repertoire was known, the question was which core chaperones DNAJC12 cooperates with and where it acts; this established it as a cytoplasmic J-protein cycling with Hsc70.

   Evidence Immunoaffinity-MS plus reciprocal endogenous Co-IP and immunofluorescence

   PMID:24122553

   Open questions at the time

   • Did not identify hydroxylase clients
   • Functional consequence of Hsc70/BiP binding unresolved
2. 2017 High

   The disease-relevant function was unknown until biallelic mutations linked DNAJC12 to hyperphenylalaninemia, establishing it as a co-chaperone required for stability and activity of aromatic amino acid hydroxylases.

   Evidence Whole-exome sequencing in patients, PAH activity assays, and Western blot in patient fibroblasts

   PMID:28132689

   Open questions at the time

   • Molecular basis of stabilization not resolved
   • No structural model of client binding
3. 2019 Medium

   It was unclear how DNAJC12 handles misfolded client; it was shown to interact with monoubiquitinated PAH and to be implicated in routing destabilized mutant PAH toward degradation.

   Evidence Co-IP from Enu1/1 mouse liver lysates and ubiquitination Western blots

   PMID:30667134

   Open questions at the time

   • E3 ligase not identified
   • Proteasome vs autophagy partitioning unresolved
4. 2020 Medium

   To test whether stabilization is general or selective, overexpression assays showed DNAJC12 rescues destabilizing PAH variants in a mutation-specific manner and stabilizes TH but not TPH2 in this system.

   Evidence Cell-based overexpression with PAH activity assays and Western blots across multiple variants

   PMID:32333439

   Open questions at the time

   • Basis of client selectivity unexplained
   • Discrepancy with later TPH binding data unresolved
5. 2024 High

   Whether DNAJC12 governs serotonergic enzymes in vivo was open; binding to TPH1/TPH2 plus a knockout mouse showing reduced PAH, TPH1, and TPH2 established its role across the full hydroxylase family and tied loss to serotonin deficiency.

   Evidence Co-transfection Co-IP and Dnajc12 knockout mouse with enzyme activity and HPLC neurotransmitter measurements

   PMID:39695187

   Open questions at the time

   • Tissue-specific contributions not dissected
   • Structural mode of TPH binding not shown
6. 2025 High

   How DNAJC12 recognizes and protects clients at atomic resolution was unknown; cryo-EM and crosslinking-MS revealed stoichiometric binding to the TH regulatory domain that leaves active sites accessible and couples client complex formation to Hsc70 ATPase stimulation.

   Evidence Cryo-EM, crosslinking-MS, in vitro aggregation, TH activity, Hsc70 ATPase assays, and C-terminal mutagenesis

   PMID:40113792

   Open questions at the time

   • J-domain/Hsc70 contact geometry not visualized
   • Handoff from holding to refolding not resolved
7. 2025 Medium

   Whether DNAJC12 extends beyond the hydroxylases to cofactor supply was open; it was shown to complex with GCH1 and to support striatal dopamine and serotonin output and TH phosphorylation state in vivo.

   Evidence Co-IP, siRNA knockdown, Dnajc12 knockout mouse, ex vivo fast-scan cyclic voltammetry, and TH phospho-Western blots

   PMID:40447642

   Open questions at the time

   • Direct vs hydroxylase-bridged GCH1 binding unresolved
   • Mechanism linking loss to altered TH phosphorylation unclear
8. 2025 Medium

   The conformational selectivity and stoichiometry of PAH recognition were unknown; in vitro reconstitution showed preference for L-Phe-activated PAH, four-monomer binding, protection from aggregation, and client-dependent Hsc70 ATPase stimulation.

   Evidence In vitro binding/affinity, aggregation, PAH activity, and Hsc70 ATPase assays (preprint)

   PMID:bio_10.1101_2025.07.18.665471

   Open questions at the time

   • Preprint, not yet peer-reviewed
   • No cryo-EM structure of the PAH complex
9. 2024 Medium

   A non-chaperone, oncogenic role was tested; DNAJC12 was shown to drive HSP70-dependent AKT phosphorylation and PI3K-AKT activation that suppresses doxorubicin-induced ferroptosis and apoptosis in breast cancer.

   Evidence Reciprocal Co-IP, RNA-seq, gain/loss-of-function in breast cancer lines, AKT inhibitor rescue, and xenograft model

   PMID:38306757

   Open questions at the time

   • Whether AKT is a direct client unresolved
   • Relationship to the hydroxylase-chaperone function unclear
10. 2022 Medium

    How DNAJC12 promotes tumor growth was probed in lung cancer, placing it upstream of β-catenin and showing HNF1A transcriptionally activates DNAJC12 to support glycolysis and chemoresistance.

    Evidence shRNA knockdown with β-catenin rescue, luciferase promoter reporter, and xenografts

    PMID:33907820 PMID:35571408

    Open questions at the time

    • Mechanistic link from DNAJC12 to β-catenin not defined
    • Connection to chaperone activity untested
11. 2030 Medium

    A metabolic-epigenetic circuit was described in which DNAJC12 loss activates glycolysis, raising lactate-driven H4K5 lactylation that upregulates COL1A1 to promote invasion.

    Evidence Knockdown, metabolic flux, H4K5la ChIP at COL1A1, and invasion assays in neuroblastoma

    PMID:39716470

    Open questions at the time

    • How DNAJC12 restrains glycolysis molecularly unresolved
    • Generalizability beyond neuroblastoma untested

• How DNAJC12's J-domain physically docks onto Hsc70 to drive substrate release/refolding, and how the same protein bridges chaperone function and oncogenic AKT/β-catenin signaling, remain unresolved.
• No structure of the DNAJC12-Hsc70 interaction
• Substrate handoff and refolding cycle not reconstituted
• Mechanistic basis of cancer signaling roles undefined